Leflunomide

Leflunomide tablets USP are indicated for the treatment of adults with active rheumatoid arthritis (RA). Leflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of adults with active rheumatoid arthritis. ( 1 )

12.1 Mechanism of Action Leflunomide is an isoxazole immunomodulatory agent that inhibits dihydroorotate dehydrogenase (a mitochondrial enzyme involved in de novo pyrimidine synthesis) and has antiproliferative activity. Several in vivo and in vitro experimental models have demonstrated an anti-inflammatory effect.

Clinical clearance of Leflunomide (Antirheumatic Agent) relies on mixed metabolic conjugation and unchanged urinary excretion across leflunomide regimens with a Terminal t½ estimated at 10–23 hrs depending on renal/hepatic reserve (Leflunomide) half-life; patients absorbing at F ≈ 73%–85% systemic availability after standard oral Leflunomide administration bioavailability typically observe target onset around time to peak concentration spans 1 to 3 hrs under leflunomide maintenance.

FDA clinical labeling for Leflunomide restricts administration in leflunomide is contraindicated in: · pregnant women.; leflunomide may cause fetal harm.; if a woman becomes pregnant while taking this drug, stop leflunomide, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure . across 10 mg/1 Tablet, 10 mg/1 Tablet, Film Coated, 20 mg/1 Tablet, Film Coated, 20 mg/1 Tablet, 100 mg/1 Tablet, Film Coated, with self-reported patient tracking dominated by nausea (10.6% of reports), headache (9.2% of reports), diarrhea (7.9% of reports).